Beinaglutide/Insulin glargine

贝那鲁肽/甘精胰岛素

Report date: 2023/08/25 17:25:54

Base Information

Drug NameBeinaglutide/Insulin glargine
Drug Alias NameBEM-041
ClassificationBiologics
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsInsulin receptor agonists
TargetsGlucagon-like peptide 1 receptorInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes BeinaglutideInsulin glargine
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Benemae Pharmaceutical Co
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Benemae Pharmaceutical Co
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A